A 12-week Treatment, Multicenter, Randomized, Double Blind, Double Dummy, Parallel-group Study to Assess the Efficacy of Indacaterol (150 microg o.d.) in Patients With Chronic Obstructive Pulmonary Disease, Using Formoterol (12 microg b.i.d.) as an Active Control.
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 27 Apr 2017
At a glance
- Drugs Formoterol; Indacaterol
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Novartis
- 02 May 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 23 Jun 2011 New trial record